TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow +1.0% ·
net new positions +8.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +3 | 260.72M | $131.51B | +5 | −1 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | — |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | — |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | — | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | — |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | — | −2 |
| Q2 2024 | 23 | — | 44.78M | $24.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 16.45M | — | $8.56B | 0.3% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 10.92M | -0.5% | $5.68B | 0.7% | ▼ Trim | 3 | SEC ↗ ×2 |
| 3 | Capital World Investors ✦ | 9.43M | +1.1% | $4.91B | 0.7% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 7.86M | +2.6% | $4.08B | 0.3% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 6.05M | +8.3% | $3.15B | 0.4% | ▲ Add | 3 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 2.67M | +1.1% | $1.39B | 0.6% | ▲ Add | 3 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 2.51M | -2.7% | $1.30B | 1.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.43M | -43.5% | $742.86M | 0.1% | ▼ Trim | 3 | SEC ↗ ×7 |
| 9 | D. E. Shaw & Co. ✦ | 543.33K | +60.8% | $282.65M | 0.3% | ▲ Add | 3 | SEC ↗ ×2 |
| 10 | Baillie Gifford ✦ | 538.86K | -10.7% | $280.33M | 0.2% | ▼ Trim | 3 | SEC ↗ ×4 |
| 11 | Two Sigma Investments ✦ | 451.83K | +13.8% | $235.06M | 0.6% | ▲ Add | 3 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 390.31K | +9.1% | $203.05M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 369.29K | +79.0% | $192.11M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 14 | Third Point ✦ | 350.00K | New | $182.08M | 2.4% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 342.38K | +179.6% | $178.12M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 339.94K | +104.5% | $176.85M | 0.2% | ▲ Add | 3 | SEC ↗ ×2 |
| 17 | Marshall Wace ✦ | 330.32K | -47.4% | $171.84M | 0.2% | ▼ Trim | 3 | SEC ↗ ×3 |
| 18 | AQR Capital Management ✦ | 221.20K | +4.6% | $115.08M | 0.1% | ▲ Add | 3 | SEC ↗ ×5 |
| 19 | Renaissance Technologies ✦ | 181.34K | +270.5% | $94.34M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 20 | Markel Group ✦ | 41.10K | +16.1% | $21.38M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 21 | Point72 Asset Management ✦ | 39.10K | New | $20.34M | 0.1% | New | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 29.35K | +25.4% | $15.27M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 23 | Dodge & Cox ✦ | 26.12K | -2.4% | $13.59M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | GAMCO Investors ✦ | 4.13K | -3.5% | $2.15M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Third Point | $182.08M | 2.4% |
| Point72 Asset Management | $20.34M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $11,944 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.73K sh · $2.29M
Officer · 400 sh · $245,752
Officer, Director · 62 sh · $38,982
Officer, Director · 33 sh · $20,677
Officer, Director · 101 sh · $63,166
Officer, Director · 79 sh · $49,613
Officer, Director · 2.15K sh · $1.35M
Officer, Director · 1.79K sh · $1.12M
Officer, Director · 3.01K sh · $1.89M
Officer, Director · 2.73K sh · $1.71M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology